Skip to main content
EMA Logo
  • Medicines
    Medicines

    • Search
    • Download
    • What we publish and when
    • Medicines under evaluation
    • National registers
    • Medicines for use outside the EU
  • Human regulatory
    Human regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Herbal products
  • Veterinary regulatory
    Veterinary regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    Committees

    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    News & events

    • News and press releases
    • Events
    • What's new
    • Committee highlights
    • Therapeutic areas: latest updates
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    Partners & networks

    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    About us

    • What we do
    • Who we are
    • How we work
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Support to research
    • Contact
    • Legal
    • Glossary
    • Search tips
    • FAQs
    • Brexit: UK withdrawal from EU

COVID-19 pandemic

All info here

QUICK LINKS

  • Latest updates
  • Treatments and vaccines
  • Guidance for developers and companies
  • COVID-19 vaccines: key facts
  • CHMP highlights: February 2021
    CHMP slider image
    MEDICINES |COMMITTEES

    CHMP highlights: February 2021

  • CHMP highlights: February 2021
    CHMP slider image
    MEDICINES |COMMITTEES

    CHMP highlights: February 2021

    EMA’s human medicines committee (CHMP) recommended six medicines for approval at its 22-25 February 2021 meeting.

  • EMA issues guidance to address coronavirus variants
    COVID-19 - EMA's opinion on variants slider
    COVID-19 |Vaccines

    EMA issues guidance to address coronavirus variants

  • EMA issues guidance to address coronavirus variants
    COVID-19 - EMA's opinion on variants slider
    COVID-19 |Vaccines

    EMA issues guidance to address coronavirus variants

    EMA has issued guidance for vaccine manufacturers planning to adapt COVID-19 vaccines to coronavirus (SARS-CoV-2) variants.

  • Global cooperation on COVID-19 medicine regulation
    ICMRA workshop reports on medicine regulation
    COVID-19 |International collaboration

    Global cooperation on COVID-19 medicine regulation

  • Global cooperation on COVID-19 medicine regulation
    ICMRA workshop reports on medicine regulation
    COVID-19 |International collaboration

    Global cooperation on COVID-19 medicine regulation

    ICMRA workshops underline international medicine regulators' commitment to align their align approaches for regulation of COVID-19 vaccines and medicines

  • Public meeting on COVID-19 vaccines: Friday 26 March
    second public meeting
    COVID-19 |VACCINES

    Public meeting on COVID-19 vaccines: Friday 26 March

  • Public meeting on COVID-19 vaccines: Friday 26 March
    second public meeting
    COVID-19 |VACCINES

    Public meeting on COVID-19 vaccines: Friday 26 March

    Apply now to join the virtual room during our third public meeting, about the approval, safety monitoring and expected impact of COVID-19 vaccines or watch live on the day.

Search for medicines
Search for information on human, veterinary or herbal medicines.
What's new
Find all the latest news and updates published on this website in one place.
FAQs
Find answers to the most frequently asked questions we receive.

Latest news

  • List item
    26/02/2021

    First oral treatment for spinal muscular atrophy (SMA) recommended for approval

    EMA has recommended granting a marketing authorisation in the European Union for the first treatment that can be given orally to patients with certain types of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle...

  • List item
    26/02/2021 COVID-19

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021

    Six new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended six medicines for approval at its February 2021 meeting. The Committee recommended granting a marketing authorisation for Evrysdi* (risdiplam), the first...

  • List item
    25/02/2021 COVID-19

    Adapting COVID-19 vaccines to SARS-CoV-2 variants: guidance for vaccine manufacturers

    EMA has issued guidance outlining the requirements for manufacturers planning to modify their COVID-19 vaccines in order to address coronavirus (SARS-CoV-2) variants . Currently, three vaccines are authorised for use in the EU: Comirnaty , COVID-19...

  • List item
    25/02/2021 COVID-19

    International cooperation to align approaches for regulation of COVID-19 vaccines and medicines

    Regulators around the globe are committed to aligning their regulatory requirements and addressing knowledge gaps to facilitate the development, authorisation and monitoring of safe, effective and high-quality vaccines and medicines against COVID-19...

  • List item
    24/02/2021 COVID-19

    EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19

    EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the monoclonal antibody regdanvimab (also known as CT-P59), which is being developed by Celltrion, for the treatment of COVID-19. The decision to start the rolling...

  • List item
    19/02/2021

    Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 16-17 February 2021

    CVMP opinions on veterinary medicinal products The Committee adopted by consensus a positive opinion for a marketing authorisation application for Credelio Plus ( lotilaner and milbemycin oxime combination) from Elanco GmbH, a new antiparasitic...

  • Load more news

Information for

Patients and carers
Featured news and updates for patients and carers
Healthcare professionals
Featured news and updates for healthcare professionals, including doctors, nurses and pharmacists
Animal health professionals
Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners
Pharmaceutical industry
Featured news and updates for pharmaceutical industry stakeholders active in the human and veterinary medicines fields
Media
Featured news and updates for journalists with a professional interest in the development and availability of medicines in the European Union
Academia
Featured news and updates for European academics and researchers in the field of medicine development

Key content

  • List item

    Product emergency hotline

  • List item

    UK’s withdrawal from the EU

  • List item

    PRIME: Priority medicines

  • List item

    Pharmacovigilance (safety monitoring)

  • List item

    Data on medicines

  • List item

    Clinical data publication

  • List item

    Careers

Services & databases

  • List item

    Account Management portal

  • List item

    eSubmission

  • List item

    EudraVigilance (human)

  • List item

    EU Veterinary Medicinal Product Database

  • List item

    Suspected adverse drug reactions database

  • List item

    Clinical data

  • List item

    SPOR data management services

  • List item

    Service Desk

  • List item

    IRIS platform

  • List item

    Public register of parallel distribution notices

  • List item

    European Vaccination Information Portal

How does EMA work?

  • List item

    What we do

  • List item

    Our role in authorisation of medicines

  • List item

    Who we are

  • List item

    Our scientific experts

  • List item

    How we work

  • List item

    What we publish

Product emergency hotline
outside working hours
About
  • Who we are
  • Human regulatory
  • Veterinary regulatory
  • Committees
Ask EMA
  • Send a question
  • FAQs
  • Access to documents
Links
  • Legal
  • Privacy
  • Complaints
  • Contacts
  • Glossary
  • Search tips
  • Business hours and holidays
Contact

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

For delivery address, see:
How to find us

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
RSS feed Twitter YouTube LinkedIn
© 1995-2021 European Medicines Agency
European Union agencies network
European Union agencies network
An agency of the European Union
European Union flag